Guficap Injection contains Caspofungin 70 mg, an echinocandin antifungal agent indicated for the treatment of invasive fungal infections. Caspofungin exerts its therapeutic effect by inhibiting the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, leading to cell lysis and death. Guficap Injection is primarily used in the management of invasive candidiasis, including candidemia, esophageal candidiasis, and other Candida infections refractory to or intolerant of other antifungal therapies. It is also indicated for the treatment of invasive aspergillosis in patients who are refractory to or intolerant of other antifungal agents. The injection is administered intravenously, with dosing adjusted based on the severity of infection and patient-specific factors such as hepatic function. Caspofungin demonstrates a favorable safety profile with common adverse effects including mild infusion-related reactions, elevated liver enzymes, and gastrointestinal disturbances. Due to its unique mechanism of action and minimal drug interactions, Guficap Injection is a valuable option in the antifungal armamentarium, particularly in critically ill patients or those with compromised immune systems. Clinical monitoring and appropriate laboratory assessments are recommended during therapy to ensure efficacy and detect potential adverse effects.